Symbravo Tablet
Product Images NDC 81968-020

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Symbravo (NDC 81968-020). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Axsome Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

3-ct Sample Bottle Label (Bottle Label 3 Ct)

Label for SYMBRAVO tablets containing 20 mg meloxicam and 10 mg rizatriptan, manufactured by Axsone Therapeutics, Inc. The label indicates the product is for oral use, prescription only, and supplied as a 3-tablet patient sample not for sale. Storage instructions and a barcode are also present.*

FDA Label Image

9-ct Bottle Label (Bottle Label 9 Ct)

Label for SYMBRAVO tablets containing 20 mg meloxicam and 10 mg rizatriptan, manufactured by Axsome Therapeutics, Inc. The label indicates a prescription product with NDC 81968-020-09, containing 9 tablets for oral use. It includes storage instructions, barcode, and a note to dispense the medication guide with each patient.*

FDA Label Image

Figure 1 (Figure01)

A line graph depicting the percentage of patients achieving pain freedom over time in hours after dosing. The graph compares four groups: SYMBRAVO, rizatriptan, meloxicam, and placebo. The y-axis represents percent achieving pain freedom, and the x-axis shows time from dose in hours, ranging from 0 to 2 hours. SYMBRAVO shows higher percentages than placebo across the time points.*

FDA Label Image

Figure 2 (Figure02)

A line chart depicting the percent of patients achieving MBS freedom over time in hours from dose, comparing SYMBRAVO, rizatriptan, meloxicam, and placebo. The x-axis shows time from 0 to 2 hours, and the y-axis shows percent achieving MBS freedom from 0% to 100%. SYMBRAVO and rizatriptan have similar trends, both showing higher percentages than meloxicam and placebo.*

FDA Label Image

Figure 3 (Figure03)

A line graph showing the percent of subjects achieving pain freedom over time in hours from dose for SYMBRAVO and placebo. The graph compares SYMBRAVO (solid line) and placebo (dashed line) with time on the horizontal axis (0 to 2 hours) and percent achieving pain freedom on the vertical axis (0% to 100%).*

FDA Label Image

Figure 4 (Figure04)

A line graph comparing the percent achieving MBS Freedom over time in hours from dose between SYMBRAVO and placebo. The vertical axis shows percent achieving MBS Freedom from 0% to 100%, and the horizontal axis shows time from 0 to 2 hours. SYMBRAVO shows a higher percent achieving MBS Freedom compared to placebo at each time point.*

FDA Label Image

3-ct Sample Carton Label (Sample Carton)

Fold-out carton label for SYMBRAVO tablets containing meloxicam and rizatriptan, 20 mg/10 mg strength. The label indicates this is a "Patient Sample" pack with 3 tablets for oral use, Rx only, and not for sale. Packaging instructions include storage temperature and medication guide dispensing. The labeler is Axsome Therapeutics, Inc., with the NDC 81968-020-03 clearly shown on the teal and yellow color-blocked design with barcode included.*

FDA Label Image

Structure (Structure01)

Chemical structure of meloxicam, an active ingredient in SYMBRAVO tablets. The diagram depicts the molecular arrangement including rings, hydroxyl, carbonyl, sulfonamide, and methyl substituents.*

FDA Label Image

Structure (Structure02)

Chemical structure diagram of meloxicam and rizatriptan. The image shows molecular representations including ring structures and functional groups typical of these active pharmaceutical ingredients in SYMBRAVO tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.